Table 7.
Comparison of performance of ComASP colistin in our study with other studies only focusing on K. pneumoniae and E. coli isolates.
| (Matuschek et al.)18 | (Carreto et al.)16 | (Galani et al.17 | This study | |
|---|---|---|---|---|
| E. coli & K. pneumoniae (n = 32, 19COL-R) | K. pneumonia (n = 76, 23COL-R) | K. pneumonia (n = 392,141COL-R) | E. coli & K. pneumonia (n = 21,12COL-R) | |
| EA | 96% | 94.7% | 94.9% | 66.67% |
| CA | 94% | 98.7% | 97.2% | 95.92% |
| MEs | 15.4% | 1.9% | 3.98% | 8.83% |
| VMEs | 0 | 0 | 0.7% | 0 |
EA: essential agreement, CA: categorical agreement, MEs: major error, VME: very major error. Table 6 above indicates ComASP results from other studies compared to results in this study. In this study, the CA, MEs and VMEs for ComASP Colistin were consistent with other studies but recorded the lowest EA.